Pluri Inc Revenue Growth Rates (PLUR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Pluri Inc   (NASDAQ: PLUR)
 

PLUR's Revenue Growth by Quarter and Year

Pluri Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PLUR/growth
https://api.csimarket.com/api/v1/companies/PLUR/fundamentals
https://api.csimarket.com/api/v1/companies/PLUR/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
PLUR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 0.76
FY 0.76





PLUR Revenue first quarter 2026 Y/Y Growth Comment
Pluri Inc reported Revenue surge of 137.19% year on year in the first quarter 2026, to $ 0.76 millions, this is lower than Pluri Inc 's recent average Revenue surge of 1581.37%.

Looking into first quarter 2026 results within Biotechnology & Pharmaceuticals industry 47 other companies have achieved higher Revenue growth. While Pluri Inc ' s Revenue doubling of 137.19% ranks overall at the positon no. 3468 in the first quarter 2026.


PLUR Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 137.19 %
FY   -

Financial Statements
Pluri Inc 's first quarter 2026 Revenue $ 0.76 millions PLUR's Income Statement
Pluri Inc 's first quarter 2025 Revenue $ 0.32 millions Quarterly PLUR's Income Statement


PLUR Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 123.24 %
FY (Year on Year)   -


Back to PLUR Growth rate Comparisons >> Back to PLUR Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #48
Healthcare Sector #472
Overall #3468

Revenue Y/Y Growth Statistics
High Average Low
48617.95 % 1581.37 % -100 %
(Dec 31 2015)   (Jun 30 2014)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #48
Healthcare Sector #472
Overall #3468
Revenue Y/Y Growth Statistics
High Average Low
48617.95 % 1581.37 % -100 %
(Dec 31 2015)   (Jun 30 2014)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Pluri Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
99387.18 % 2750.67 % -100 %
(Mar 31 2013)  


PLUR's I. Quarter Q/Q Revenue Comment
Pluri Inc achieved in the I. Quarter 2026 below company average Revenue doubling of 123.24% quarter on quarter, to $ 0.76 millions.

Although the I. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the I. Quarter surge, eclipses the -20% growth in the I. Quarter a year ago

Within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Pluri Inc 's Revenue growth quarter on quarter, overall rank is 138.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #44
Overall #138
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #44
Overall #138
Revenue Q/Q Growth Statistics
High Average Low
99387.18 % 2750.67 % -100 %
(Mar 31 2013)  


PLUR's I. Quarter Q/Q Revenue Comment
Pluri Inc achieved in the I. Quarter 2026 below company average Revenue doubling of 123.24% quarter on quarter, to $ 0.76 millions.

I. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -20% in the I. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Revenue quarter on quarter growth. While Pluri Inc 's Revenue growth quarter on quarter, overall rank is 138.


Pluri Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 1.46
Y / Y Revenue Growth (TTM) 10.03 %
Year on Year Revenue Growth Overall Ranking # 65
Seqeuential Revenue Change (TTM) 43.6 %
Seq. Revenue Growth (TTM) Overall Ranking # 572


Cumulative Revenue growth Comment
Although Pluri Inc 's Annual Revenue growth year on year were below company's average 75.64% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 10.03% year on year, from -23.95% in Jun 30 2026.

Among companies within the Healthcare sector 20 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 65, from total ranking in previous quarter at 74.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 21
Healthcare Sector # 21
Overall # 65

Revenue TTM Y/Y Growth Statistics
High Average Low
701.06 %
 75.64 %
-44.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 21
Sector # 127
S&P 500 # 572
Cumulative Revenue growth Comment
Although Pluri Inc 's Annual Revenue growth year on year were below company's average 75.64% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 10.03% year on year, from -23.95% in Jun 30 2026.

Among companies within the Healthcare sector 20 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 65, from total ranking in previous quarter at 74.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 21
Healthcare Sector # 21
Overall # 65

Revenue TTM Y/Y Growth Statistics
High Average Low
701.06 %
75.64 %
-44.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 21
Sector # 127
S&P 500 # 572




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PLUR's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Urogen Pharma Ltd 227.16%$ 227.161 millions
Dianthus Therapeutics Inc 205.56%$ 205.556 millions
Bridgebio Pharma Inc 192.60%$ 192.602 millions
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Alpha Cognition Inc.173.75%$ 173.751 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Volitionrx Limited157.28%$ 157.283 millions
Neuraxis Inc 149.92%$ 149.922 millions
Pluri Inc 140.19%$ 140.190 millions
Camp4 Therapeutics Corporation138.87%$ 138.868 millions
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions


About Pluri Inc Revenue Growth Rates (PLUR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Pluri Inc (CIK 1158780).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-26-118901
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Pluri Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.